Search
NeOnc Technologies Holdings Inc
NTHIAdd to Watchlist
4.420USD
-0.040-0.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
97.20MMarket Cap
LossP/E TTM
More Details of NeOnc Technologies Holdings Inc Company
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
NeOnc Technologies Holdings Inc Info
Ticker SymbolNTHI
Company nameNeOnc Technologies Holdings Inc
IPO dateMar 26, 2025
CEOHeshmatpour (Amir F)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMar 26
Address23975 Park Sorrento
CityCALABASAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91302
Phone13106637831
Websitehttps://neonc.com/
Ticker SymbolNTHI
IPO dateMar 26, 2025
CEOHeshmatpour (Amir F)
Company Executives of NeOnc Technologies Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Hon. Jim Delshad
Hon. Jim Delshad
Independent Director
Independent Director
--
--
Ms. Laurie Berman
Ms. Laurie Berman
Investor Relations
Investor Relations
--
--
Mr. Josh Neman
Mr. Josh Neman
Chief Clinical Officer
Chief Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of NeOnc Technologies Holdings Inc?
The top five shareholders of NeOnc Technologies Holdings Inc are: Mr. Bader Almonawer